Verona Pharma Announces May 2022 Investor Conference Participation

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) announced its participation in two key conferences in May 2022. The LifeSci Partners Virtual Immunology & Inflammation Symposium will take place on May 10 at 9:00 AM ET, and the H.C. Wainwright Hybrid Global Investment Conference is scheduled for May 24 at 3:30 PM ET in Miami. Verona Pharma is advancing its Phase 3 clinical program for nebulized ensifentrine, aimed at COPD treatment, with expected top-line data in Q3 2022. Ensifentrine could potentially be a breakthrough therapy combining bronchodilator and anti-inflammatory properties.

Positive

• Participation in major industry conferences, enhancing visibility.
• Progressing in Phase 3 clinical program for ensifentrine, with data expected in Q3 2022.
• Potential to pioneer a unique therapy for respiratory diseases.

Negative

• None.

LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022:

LifeSci Partners Virtual Immunology & Inflammation Symposium

Date: Tuesday, May 10
Time: 9:00 AM ET / 2:00 PM BST
Location: Virtual

H.C. Wainwright Hybrid Global Investment Conference

Date: Tuesday, May 24
Time: 3:30 PM ET / 8:30 PM BST
Location: Miami, Florida

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on respiratory diseases. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Top-line data are expected in the third quarter of 2022 and around the end of 2022.

If successfully developed and approved, ensifentrine has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

For further information please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications	info@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Kimberly Minarovich / Michael Barron
Optimum Strategic Communications (International Media and European Investor Enquiries)	Tel: +44 (0)203 950 9144 verona@optimumcomms.com
Mary Clark / Rebecca Noonan / Zoe Bolt

FAQ

What are the upcoming conferences Verona Pharma will attend in May 2022?

Verona Pharma will attend the LifeSci Partners Virtual Immunology & Inflammation Symposium on May 10 and the H.C. Wainwright Hybrid Global Investment Conference on May 24.

What is ensifentrine and its significance for Verona Pharma?

Ensifentrine is a drug being evaluated by Verona Pharma in its Phase 3 program for COPD. It may become the first therapy to combine bronchodilator and anti-inflammatory effects.

When can investors expect top-line data for ensifentrine?

Top-line data for ensifentrine is expected in the third quarter of 2022.

What are the potential applications of ensifentrine?

Ensifentrine has potential applications in treating COPD, cystic fibrosis, asthma, and other respiratory diseases.